Medezin: one position from Australia and the trap of two names

• Scale. 1 strain in the list, in 1 pharmaceutical position.
• What you won’t buy elsewhere. 1 of them is supplied exclusively by this manufacturer, so a break in its supply means no versions of these strains, not another version.
• Portfolio profile. Myrcene leads, in 1 of 1 strains.
• What is missing. For 1 of 1 strains, the pedigree remains unestablished and we do not add it by similarity of name.

Who is Medezin and where does its cannabis come from?

Medezin is a pharmaceutical company from Łódź, which is responsible for one position with cannabis flower in Polish trade. It does not cultivate plants: the raw material comes from Australia, from the company Little Green Pharma, and Medezin is listed as the responsible entity, meaning the party importing the goods to the country and responsible for its trade.

The company’s own website describes it without a single word about cannabis. It mentions the import and certification of medicines, distribution, storage, and repackaging, provides an address in Łódź and a facility in Konstantynów Łódzki. Cannabis flower is just one of many things that can be imported and distributed, not a separate line described in the offer.

The company is backed by Pelion, the largest healthcare operator in Poland and Lithuania, owner of a pharmaceutical wholesaler and a chain of pharmacies. Industry reports indicate the year 2023 as the moment of entering the raw material into circulation, and the first packages reached pharmacies in March 2024. Sources even disagree on the legal form: the pharmacy database and the company’s own website refer to a limited liability company, while market reviews mention a joint-stock company.

In this arrangement, the manufacturer and the responsible entity are not the same. The Australian company conducts cultivation and prepares the raw material, while the Polish company takes on the introduction of it into circulation and contact with authorities. The name on the pharmacy packaging belongs to the latter, so the patient reads the name of the importer, not the name of the plantation. Therefore, in our list, this position stands under Medezin, even though no bush grew in Poland.

Which strains of Medezin reach Polish pharmacies?

One. In our list of one hundred forty-one pharmaceutical positions, Medezin has exactly one entry, Desert Flame, and the same is indicated by the profile database. Such a narrow offer is also held by two other suppliers, while the largest of the sixteen manufacturers is responsible for thirty-eight strains.

The declared THC content is in the range of 18.0-22.0%. The profile source provides one nominal value and allows a deviation of ten percent in either direction, hence the range instead of a single number: between batches of the same product, the analysis does not come out identically twice. The declared CBD content is less than one percent.

One position at the supplier means something different for the patient than one position in the catalog. With thirty-eight labels from one manufacturer, a break in supply can usually be circumvented by another label from the same company. Here, there is no such reserve: when this position disappears from circulation, the entire share of this supplier in the flower market disappears with it, and a person who has tailored their therapy to it returns to choosing between manufacturers.

The leading terpene of this position does not distinguish it from the list. Myrcene is at the forefront of the profile in twenty of the eighty-five strains we have collected, so in this respect, Desert Flame falls into the most numerous family in Polish pharmacies. Separately, the number of packages stands out: it is one of fifty-eight strains for which there is exactly one pharmaceutical position in the entire list.

How does Medezin’s raw material differ from that of other suppliers?

By process rather than plant. Medezin does not conduct cultivation or extraction: it imports ready-made flower from the Australian plantation, certifies it, and introduces it into circulation. The difference compared to suppliers with their own cultivation lies, therefore, in the supply chain and the trade agreement, not in the technology of producing the raw material itself.

The pharmacy record indicates only this: floral form, fifteen-gram packaging, designation of a narcotic substance, and a note about dispensing by prescription. The rest of what circulates about this company comes from the stock market announcement of the Australian partner. It describes a five-year agreement for the distribution of oils and flower and exclusivity dependent on sales thresholds: one-fifth of the oil market and one-tenth of the high-potency flower market.

The commercial declaration is not a quality document. The distribution agreement speaks of ambitions for market share, not of how a specific batch was grown and dried. Neither the pharmacy database nor the company’s website publish a certificate of analysis for the batch, so comparing this raw material with that of another supplier can only be done today at the label level.

One point from the same announcement, however, directly concerns quality. The parties announced the signing of a technical agreement under good manufacturing practice before the first shipment, meaning the requirements for the product were established by contract between the companies. The contents of this contract have not been published, so the reader knows only that the document exists. This is where the boundary lies, where fact ends and assurance begins.

What is known and what is not known about this supplier’s raw material?

What is on the packaging is known, and almost nothing beyond that. The pharmacy database provides the responsible entity, floral form, and weight and declared potency. There is no public certificate of analysis, no name of the laboratory, nor clinical study conducted on this company’s raw material, and market reports speak of one delivery.

The terpene profile of this position is described by one Polish strain database and no one else. It lists five components with myrcene at the forefront, alongside caryophyllene, limonene, humulene, and pinene. The leading terpene collects strains with a similar profile on a separate page. We do not transcribe percentage shares from here because it is unknown what they are calculated against.

This is evident in its own number. The five values given for this position sum to 78 percent, and the same five in the clinical description stand next to a sixth column simply named others, which completes one hundred. In the same database, one hundred forty-five positions yield forty-six different sums, from fourteen to one hundred twenty-five, with a median of eighty-two. A number that sometimes represents a part of the whole and sometimes a part of a known part is not a measurement.

The third group is relations. A public patient review describes the appearance and smell of this batch and directly indicates the Australian origin of the flower, but does not refer to any laboratory document. Such a text is a testament to the experience of one person, and we treat it as such here.

What adverse effects have been reported after using Medezin’s raw material?

None separately. There is no public compilation of reports attributed to this manufacturer or this one position, and with one delivery to pharmacies, the number of people who used it is too small for any registry to count anything from it. The following therefore applies to the entire group of raw material.

Reports of adverse effects are collected for a medicinal product with a batch number, not for the strain name, so the following applies to cannabis flower as a group of raw materials. The most commonly reported effects are dry mouth, red eyes, and increased heart rate. Less frequently described are dizziness upon rapid standing, daytime drowsiness, and temporary worsening of short-term memory, as well as anxiety that increases with dosage. A separate issue is medications taken concurrently, especially sedatives and those affecting coagulation: their assessment requires knowledge of the entire list of preparations, not a description of the plant. We do not provide the frequency of these symptoms numerically because public compilations for cannabis flower in Poland do not separate them by individual products.

This position also adds the route of administration. The flower reaches the pharmacy in floral form, so it is sometimes vaporized or brewed as an infusion, which shifts both the threshold for the appearance of symptoms and the duration of their occurrence. The choice of route of administration and portion size is up to the attending physician, not the description of the strain.

Why is the composition of this position so easy to lose in strain databases?

Because the same position has three different names and none of them is complete. The pharmacy list lists it as Desert Flame, the profile database titled it Amnesia Haze with Desert Flame in parentheses, and the registered name does not contain the strain name at all, as it only refers to the manufacturer and potency.

Amnesia Haze does not appear in the Polish list as a separate strain, yet it holds the first place in the title of the profile page and in its address. Our stream keyed source positions by the base name extracted from the address, so the record with the full composition fell under a term that does not exist in the inventory and quietly fell out of agreement. Until August 30, 2026, the page about this strain claimed that the composition could not be established, even though a file with five names lay in the same repository.

The fix is easy to describe and unpleasant to find: when the title of the position names the inventory entry more accurately than the base name, the title prevails. Verified on all one hundred forty-six positions of both profile databases, the rule keyed exactly four records and did not touch any others. A practical conclusion for anyone looking for data on flower by trade name: also check under the alternative name in parentheses and under the registered name, because the strain database search engine will show emptiness where data exists, just under a different term.

Is Medezin’s only position currently available in pharmacies?

Checked on August 30, 2026: the profile database shows availability for this position described as none. An entry in the list and presence on the shelf are two different things, and industry reports speak of a single delivery, after which the goods disappeared. Availability changes faster than any description of a strain.

There are several reasons, and none of them concern the quality of the flower itself. The permit for the trade of pharmaceutical raw material is valid for years, and one delivery is enough for several months of sales. The importer orders another batch when it sees demand and when the partner on the other side of the world has something to cover it, and between one and the other, a year can pass. The distance adds to this: the batch travels from Australia, so the usual order cycle must include transport and customs clearance, and delays on the other side are visible on the Polish shelf with a several-month delay.

That is why we keep the current state in one place, not in strain descriptions: the list of currently available medical marijuana strains is refreshed along with the list and only there does it make sense to check what is on the pharmacy shelf today. The profile, pedigree, and what is not known about this strain are described separately in the text about the strain Desert Flame. A completely different group of goods is the store category hemp flower, available without a prescription and not a substitute for pharmaceutical raw material.

Frequently asked questions about flower from Medezin

How many strains does Medezin supply to Polish pharmacies?

One. In the list of one hundred forty-one pharmaceutical positions, the company has one entry, Desert Flame, and no other strain is assigned to it.

Where does the flower sold under the name Desert Flame come from?

From Australia, from the cultivation of Little Green Pharma. Medezin imports it to Poland as the responsible entity and does not conduct its own cultivation.

Why does the same position appear under two names?

The profile database lists it as Amnesia Haze with the note Desert Flame in parentheses, while the Polish pharmacy list uses only the name Desert Flame. The registered name does not contain either of them.

Does Medezin publish a certificate of analysis for its flower?

We did not find such a document either on the company’s website or in pharmacy databases. Publicly available are only the data from the label.

What THC content is declared for this position?

The range is 18.0-22.0%, which is the nominal value with an allowable deviation of ten percent in either direction. We do not provide a single number because it does not reflect the variability between batches.

Can flower from Medezin be purchased without a prescription?

No. Cannabis flower is a pharmaceutical raw material dispensed by a doctor’s prescription in the Rpw category, so it is not available outside pharmacies and without a prescription.

Can this strain be purchased in a pharmacy today?

The profile database shows availability for it described as none, checked on August 30, 2026. We collect the current state in the cluster hub because it changes faster than strain descriptions.

Cannabis flower is a pharmaceutical raw material dispensed by a doctor’s prescription in the Rpw category. The material is for informational purposes, describes the state of evidence, and does not replace consultation with the attending physician. Editorial text: Editorial team ubucha.pl.